ERBB2 and breast cancer: For instance, Wiklander et al. developed EVs displaying Fc‐binding domains on their membranes, which allowed modular attachment of therapeutic antibodies such as trastuzumab or atezolizumab.[177] These antibody‐decorated EVs demonstrated enhanced receptor‐specific uptake in HER2+ breast cancer and PD‐L1+ melanoma cells, achieving up to a 509‐fold increase in cellular internalization and improved in vivo tumor accumulation.